image
Healthcare - Medical - Devices - NYSE - US
$ 4.52
11.1 %
$ 169 M
Market Cap
-2.42
P/E
1. INTRINSIC VALUE

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.[ Read More ]

The intrinsic value of one NVRO stock under the base case scenario is HIDDEN Compared to the current market price of 4.52 USD, Nevro Corp. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVRO

image
FINANCIALS
425 M REVENUE
4.63%
-99.3 M OPERATING INCOME
-0.48%
-92.2 M NET INCOME
-3072.74%
-58.8 M OPERATING CASH FLOW
-238.42%
-7.2 M INVESTING CASH FLOW
-11.21%
49.5 M FINANCING CASH FLOW
2116.04%
96.9 M REVENUE
-6.96%
-13.9 M OPERATING INCOME
44.80%
-15.3 M NET INCOME
21.61%
3.06 M OPERATING CASH FLOW
137.44%
-6.44 M INVESTING CASH FLOW
32.46%
-682 K FINANCING CASH FLOW
-34.15%
Balance Sheet Decomposition Nevro Corp.
image
Current Assets 531 M
Cash & Short-Term Investments 323 M
Receivables 79.4 M
Other Current Assets 129 M
Non-Current Assets 105 M
Long-Term Investments 0
PP&E 33.5 M
Other Non-Current Assets 71.3 M
Current Liabilities 83.4 M
Accounts Payable 22.5 M
Short-Term Debt 5.72 M
Other Current Liabilities 55.1 M
Non-Current Liabilities 259 M
Long-Term Debt 216 M
Other Non-Current Liabilities 43.1 M
EFFICIENCY
Earnings Waterfall Nevro Corp.
image
Revenue 425 M
Cost Of Revenue 135 M
Gross Profit 290 M
Operating Expenses 389 M
Operating Income -99.3 M
Other Expenses -7.1 M
Net Income -92.2 M
RATIOS
68.22% GROSS MARGIN
68.22%
-23.36% OPERATING MARGIN
-23.36%
-21.69% NET MARGIN
-21.69%
-31.46% ROE
-31.46%
-14.51% ROA
-14.51%
-18.54% ROIC
-18.54%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nevro Corp.
image
Net Income -92.2 M
Depreciation & Amortization 11.5 M
Capital Expenditures -8.59 M
Stock-Based Compensation 56.9 M
Change in Working Capital -39.7 M
Others -10.6 M
Free Cash Flow -67.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nevro Corp.
image
Wall Street analysts predict an average 1-year price target for NVRO of $8.32 , with forecasts ranging from a low of $5 to a high of $16 .
NVRO Lowest Price Target Wall Street Target
5 USD 10.62%
NVRO Average Price Target Wall Street Target
8.32 USD 84.10%
NVRO Highest Price Target Wall Street Target
16 USD 253.98%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Nevro Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 07, 2023
Bought 172 K USD
McCormick Shawn
Director
+ 7500
22.8844 USD
2 years ago
May 09, 2022
Bought 100 K USD
Rashid Kashif
General Counsel
+ 2250
44.5005 USD
2 years ago
Mar 11, 2022
Bought 96.1 K USD
Rashid Kashif
General Counsel
+ 1500
64.0448 USD
2 years ago
Mar 08, 2022
Bought 203 K USD
GROSSMAN D KEITH
Chairman, President & CEO
+ 3200
63.59 USD
2 years ago
Dec 14, 2021
Bought 117 K USD
OBOYLE KEVIN C
Director
+ 1400
83.8 USD
2 years ago
Dec 14, 2021
Bought 83.8 K USD
OBOYLE KEVIN C
Director
+ 1000
83.75 USD
2 years ago
Nov 22, 2021
Bought 918 K USD
WEATHERMAN ELIZABETH H
Director
+ 10703
85.7376 USD
2 years ago
Nov 22, 2021
Bought 789 K USD
WEATHERMAN ELIZABETH H
Director
+ 9297
84.8552 USD
3 years ago
Nov 11, 2021
Bought 202 K USD
Rashid Kashif
General Counsel
+ 2000
101.05 USD
3 years ago
Aug 13, 2021
Bought 735 K USD
GROSSMAN D KEITH
Chairman, President & CEO
+ 7000
105.07 USD
3 years ago
Jun 22, 2021
Sell 1.15 M USD
DEMANE MICHAEL F
Director
- 6445
179.0283 USD
3 years ago
May 24, 2021
Sell 72.1 K USD
McCormick Shawn
Director
- 482
149.65 USD
3 years ago
Mar 10, 2021
Sell 111 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
148.08 USD
3 years ago
Mar 01, 2021
Sell 83.5 K USD
Vale Brad
Director
- 503
166.0511 USD
3 years ago
Mar 01, 2021
Sell 336 K USD
Vale Brad
Director
- 2012
167.0429 USD
3 years ago
Mar 01, 2021
Sell 215 K USD
Vale Brad
Director
- 1278
168.3158 USD
3 years ago
Mar 01, 2021
Sell 255 K USD
Vale Brad
Director
- 1510
169.0844 USD
3 years ago
Feb 10, 2021
Sell 137 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
182.55 USD
3 years ago
Jan 11, 2021
Sell 127 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
169.8 USD
3 years ago
Dec 10, 2020
Sell 48.6 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 300
161.96 USD
3 years ago
Dec 10, 2020
Sell 72.3 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 450
160.715 USD
4 years ago
Nov 10, 2020
Sell 128 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
170.75 USD
4 years ago
Oct 22, 2020
Sell 300 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 1817
165 USD
4 years ago
Oct 19, 2020
Sell 155 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 1000
155 USD
4 years ago
Oct 13, 2020
Sell 114 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
151.47 USD
4 years ago
Oct 09, 2020
Sell 150 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 1000
150 USD
4 years ago
Oct 09, 2020
Sell 3.09 M USD
DEMANE MICHAEL F
Director
- 20529
150.3115 USD
4 years ago
Oct 12, 2020
Sell 106 K USD
DEMANE MICHAEL F
Director
- 703
151.0934 USD
4 years ago
Oct 12, 2020
Sell 30.3 K USD
DEMANE MICHAEL F
Director
- 200
151.62 USD
4 years ago
Sep 15, 2020
Sell 291 K USD
DEMANE MICHAEL F
Director
- 2000
145.273 USD
4 years ago
Sep 16, 2020
Sell 728 K USD
DEMANE MICHAEL F
Director
- 5002
145.5274 USD
4 years ago
Sep 16, 2020
Sell 876 K USD
DEMANE MICHAEL F
Director
- 5977
146.585 USD
4 years ago
Sep 16, 2020
Sell 615 K USD
DEMANE MICHAEL F
Director
- 4169
147.4127 USD
4 years ago
Sep 16, 2020
Sell 130 K USD
DEMANE MICHAEL F
Director
- 880
148.1942 USD
4 years ago
Sep 10, 2020
Sell 104 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
139.14 USD
4 years ago
Sep 02, 2020
Sell 494 K USD
DEMANE MICHAEL F
Director
- 3400
145.2541 USD
4 years ago
Aug 27, 2020
Sell 1.14 M USD
DEMANE MICHAEL F
Director
- 8081
140.5528 USD
4 years ago
Aug 27, 2020
Sell 1.53 M USD
DEMANE MICHAEL F
Director
- 10819
141.3436 USD
4 years ago
Aug 13, 2020
Sell 42 K USD
DEMANE MICHAEL F
Director
- 300
140.0533 USD
4 years ago
Aug 10, 2020
Sell 4.09 M USD
DEMANE MICHAEL F
Director
- 30469
134.3417 USD
4 years ago
Aug 10, 2020
Sell 2.68 M USD
DEMANE MICHAEL F
Director
- 19785
135.5825 USD
4 years ago
Aug 10, 2020
Sell 3.3 M USD
DEMANE MICHAEL F
Director
- 24208
136.1837 USD
4 years ago
Aug 10, 2020
Sell 528 K USD
DEMANE MICHAEL F
Director
- 3813
138.439 USD
4 years ago
Aug 10, 2020
Sell 325 K USD
DEMANE MICHAEL F
Director
- 2337
138.8748 USD
4 years ago
Aug 10, 2020
Sell 396 K USD
DEMANE MICHAEL F
Director
- 2828
140.11 USD
4 years ago
Aug 10, 2020
Sell 219 K USD
DEMANE MICHAEL F
Director
- 1626
134.4178 USD
4 years ago
Aug 10, 2020
Sell 200 K USD
DEMANE MICHAEL F
Director
- 1474
135.6428 USD
4 years ago
Aug 10, 2020
Sell 136 K USD
DEMANE MICHAEL F
Director
- 1000
136.373 USD
4 years ago
Aug 10, 2020
Sell 55.5 K USD
DEMANE MICHAEL F
Director
- 400
138.6975 USD
4 years ago
Aug 10, 2020
Sell 105 K USD
Pellegrini Niamh Louise
Chief Commercial Officer
- 750
140.11 USD
4 years ago
May 21, 2020
Sell 129 K USD
McCormick Shawn
Director
- 1020
126.5 USD
4 years ago
Feb 28, 2020
Sell 582 K USD
Schmitz Patrick
Vice President, Operations
- 4604
126.4693 USD
4 years ago
Feb 28, 2020
Sell 941 K USD
Schmitz Patrick
Vice President, Operations
- 7404
127.0628 USD
4 years ago
Feb 28, 2020
Sell 354 K USD
Schmitz Patrick
Vice President, Operations
- 2758
128.253 USD
4 years ago
Feb 28, 2020
Sell 2.23 M USD
Schmitz Patrick
Vice President, Operations
- 17205
129.3381 USD
4 years ago
Feb 28, 2020
Sell 1.34 M USD
Schmitz Patrick
Vice President, Operations
- 10313
130.1326 USD
4 years ago
Feb 28, 2020
Sell 78.5 K USD
Schmitz Patrick
Vice President, Operations
- 600
130.825 USD
4 years ago
Jan 08, 2020
Sell 2.13 M USD
Galligan Andrew H
Chief Financial Officer
- 17718
120.1087 USD
4 years ago
Jan 06, 2020
Sell 334 K USD
Galligan Andrew H
Chief Financial Officer
- 2782
120 USD
4 years ago
Nov 25, 2019
Sell 1.32 M USD
Galligan Andrew H
Chief Financial Officer
- 12000
110.3928 USD
4 years ago
Nov 25, 2019
Sell 110 K USD
Alleavitch Doug
VP, Quality
- 1000
110 USD
5 years ago
Nov 11, 2019
Sell 83.5 K USD
McCormick Shawn
Director
- 800
104.35 USD
5 years ago
Nov 11, 2019
Sell 853 K USD
DEMANE MICHAEL F
Director
- 8274
103.0713 USD
5 years ago
Nov 11, 2019
Sell 3.85 M USD
DEMANE MICHAEL F
Director
- 37116
103.7229 USD
5 years ago
Nov 11, 2019
Sell 483 K USD
DEMANE MICHAEL F
Director
- 4610
104.6794 USD
5 years ago
Nov 11, 2019
Sell 723 K USD
Galligan Andrew H
Chief Financial Officer
- 7002
103.3089 USD
5 years ago
Nov 11, 2019
Sell 1.07 M USD
Galligan Andrew H
Chief Financial Officer
- 10345
103.846 USD
5 years ago
Nov 11, 2019
Sell 123 K USD
Galligan Andrew H
Chief Financial Officer
- 1175
104.7448 USD
5 years ago
Nov 07, 2019
Sell 100 K USD
Alleavitch Doug
VP, Quality
- 1000
100 USD
5 years ago
Jun 07, 2019
Bought 150 K USD
WEATHERMAN ELIZABETH H
Director
+ 2460
60.9867 USD
5 years ago
Jun 06, 2019
Bought 254 K USD
WEATHERMAN ELIZABETH H
Director
+ 4128
61.4528 USD
5 years ago
Jun 06, 2019
Bought 97.3 K USD
WEATHERMAN ELIZABETH H
Director
+ 1595
60.9887 USD
5 years ago
Jun 05, 2019
Bought 100 K USD
OBOYLE KEVIN C
Director
+ 1675
60 USD
6 years ago
May 14, 2018
Sell 533 K USD
Galligan Andrew H
Chief Financial Officer
- 7000
76.137 USD
6 years ago
Mar 05, 2018
Sell 3.3 M USD
JAEGER WILFRED E
Director
- 41206
80.186 USD
6 years ago
Mar 06, 2018
Sell 4 M USD
JAEGER WILFRED E
Director
- 49742
80.3807 USD
6 years ago
Mar 07, 2018
Sell 5.38 M USD
JAEGER WILFRED E
Director
- 66125
81.4222 USD
6 years ago
Mar 05, 2018
Sell 73 K USD
JAEGER WILFRED E
Director
- 910
80.186 USD
6 years ago
Mar 06, 2018
Sell 88.3 K USD
JAEGER WILFRED E
Director
- 1098
80.3807 USD
6 years ago
Mar 07, 2018
Sell 119 K USD
JAEGER WILFRED E
Director
- 1461
81.4222 USD
6 years ago
Mar 01, 2018
Sell 443 K USD
Galligan Andrew H
Chief Financial Officer
- 5540
79.8999 USD
6 years ago
Mar 01, 2018
Sell 118 K USD
Galligan Andrew H
Chief Financial Officer
- 1460
80.867 USD
6 years ago
Feb 27, 2018
Sell 98.8 K USD
JAEGER WILFRED E
Director
- 1174
84.1725 USD
6 years ago
Feb 27, 2018
Sell 1.08 M USD
JAEGER WILFRED E
Director
- 12972
83.1979 USD
6 years ago
Feb 28, 2018
Sell 652 K USD
JAEGER WILFRED E
Director
- 7844
83.0942 USD
6 years ago
Feb 28, 2018
Sell 556 K USD
JAEGER WILFRED E
Director
- 6832
81.3625 USD
6 years ago
Mar 01, 2018
Sell 787 K USD
JAEGER WILFRED E
Director
- 9784
80.4843 USD
6 years ago
Feb 27, 2018
Sell 2.19 K USD
JAEGER WILFRED E
Director
- 26
84.1725 USD
6 years ago
Feb 27, 2018
Sell 23.8 K USD
JAEGER WILFRED E
Director
- 286
83.1979 USD
6 years ago
Feb 28, 2018
Sell 14.4 K USD
JAEGER WILFRED E
Director
- 173
83.0942 USD
6 years ago
Feb 28, 2018
Sell 12.3 K USD
JAEGER WILFRED E
Director
- 151
81.3625 USD
6 years ago
Mar 01, 2018
Sell 17.4 K USD
JAEGER WILFRED E
Director
- 216
80.4843 USD
7 years ago
Nov 14, 2017
Sell 526 K USD
Galligan Andrew H
Chief Financial Officer
- 7000
75.1057 USD
7 years ago
Oct 05, 2017
Sell 468 K USD
DEMANE MICHAEL F
Director
- 5000
93.5 USD
7 years ago
Sep 27, 2017
Sell 458 K USD
DEMANE MICHAEL F
Director
- 5000
91.5 USD
7 years ago
Sep 14, 2017
Sell 285 K USD
JAEGER WILFRED E
Director
- 3176
89.7151 USD
7 years ago
Sep 14, 2017
Sell 1.17 M USD
JAEGER WILFRED E
Director
- 12935
90.3102 USD
7 years ago
Sep 14, 2017
Sell 6.28 K USD
JAEGER WILFRED E
Director
- 70
89.7151 USD
7 years ago
Sep 14, 2017
Sell 25.8 K USD
JAEGER WILFRED E
Director
- 286
90.3102 USD
7 years ago
Sep 13, 2017
Sell 448 K USD
DEMANE MICHAEL F
Director
- 5000
89.5 USD
7 years ago
Sep 11, 2017
Sell 1.81 M USD
DEMANE MICHAEL F
Director
- 20650
87.5886 USD
7 years ago
Sep 11, 2017
Sell 384 K USD
DEMANE MICHAEL F
Director
- 4350
88.3894 USD
7 years ago
Aug 22, 2017
Sell 1.67 M USD
JAEGER WILFRED E
Director
- 19568
85.1732 USD
7 years ago
Aug 22, 2017
Sell 1.69 M USD
JAEGER WILFRED E
Director
- 19568
86.4806 USD
7 years ago
Aug 23, 2017
Sell 443 K USD
JAEGER WILFRED E
Director
- 5094
87.0116 USD
7 years ago
Aug 24, 2017
Sell 623 K USD
JAEGER WILFRED E
Director
- 7156
87 USD
7 years ago
Aug 22, 2017
Sell 36.8 K USD
JAEGER WILFRED E
Director
- 432
85.1732 USD
7 years ago
Aug 22, 2017
Sell 37.4 K USD
JAEGER WILFRED E
Director
- 432
86.4806 USD
7 years ago
Aug 23, 2017
Sell 9.75 K USD
JAEGER WILFRED E
Director
- 112
87.0116 USD
7 years ago
Aug 24, 2017
Sell 13.7 K USD
JAEGER WILFRED E
Director
- 158
87 USD
7 years ago
Aug 17, 2017
Sell 1.26 M USD
JAEGER WILFRED E
Director
- 15012
84.0188 USD
7 years ago
Aug 21, 2017
Sell 2.07 M USD
JAEGER WILFRED E
Director
- 24460
84.4445 USD
7 years ago
Aug 17, 2017
Sell 27.8 K USD
JAEGER WILFRED E
Director
- 331
84.0188 USD
7 years ago
Aug 21, 2017
Sell 45.6 K USD
JAEGER WILFRED E
Director
- 540
84.4445 USD
7 years ago
Aug 14, 2017
Sell 2.04 M USD
JAEGER WILFRED E
Director
- 24709
82.4002 USD
7 years ago
Aug 15, 2017
Sell 2.4 M USD
JAEGER WILFRED E
Director
- 29024
82.5358 USD
7 years ago
Aug 16, 2017
Sell 1.12 M USD
JAEGER WILFRED E
Director
- 13501
82.7514 USD
7 years ago
Aug 16, 2017
Sell 899 K USD
JAEGER WILFRED E
Director
- 10701
84.0416 USD
7 years ago
Aug 14, 2017
Sell 45 K USD
JAEGER WILFRED E
Director
- 546
82.4002 USD
7 years ago
Aug 15, 2017
Sell 52.9 K USD
JAEGER WILFRED E
Director
- 641
82.5358 USD
7 years ago
Aug 16, 2017
Sell 24.7 K USD
JAEGER WILFRED E
Director
- 299
82.7514 USD
7 years ago
Aug 16, 2017
Sell 19.8 K USD
JAEGER WILFRED E
Director
- 236
84.0416 USD
7 years ago
Aug 14, 2017
Sell 576 K USD
Galligan Andrew H
Chief Financial Officer
- 7000
82.3132 USD
7 years ago
May 15, 2017
Sell 261 K USD
Galligan Andrew H
Chief Financial Officer
- 3496
74.6928 USD
7 years ago
May 15, 2017
Sell 204 K USD
Galligan Andrew H
Chief Financial Officer
- 2698
75.5472 USD
7 years ago
May 15, 2017
Sell 99.8 K USD
Galligan Andrew H
Chief Financial Officer
- 1306
76.4027 USD
7 years ago
May 01, 2017
Sell 950 K USD
Elghandour Rami
President & CEO
- 10000
95.0302 USD
7 years ago
May 01, 2017
Sell 1.31 M USD
DEMANE MICHAEL F
Director
- 13800
95 USD
7 years ago
May 02, 2017
Sell 1.55 M USD
DEMANE MICHAEL F
Director
- 16000
97 USD
7 years ago
Apr 04, 2017
Sell 112 K USD
Enxing Michael
VP of Sales
- 1200
93.2888 USD
7 years ago
Apr 04, 2017
Sell 28.3 K USD
Enxing Michael
VP of Sales
- 300
94.4783 USD
7 years ago
Apr 04, 2017
Sell 1.87 M USD
DEMANE MICHAEL F
Director
- 20000
93.2567 USD
7 years ago
Apr 04, 2017
Sell 179 K USD
DEMANE MICHAEL F
Director
- 1900
94.4698 USD
7 years ago
Apr 04, 2017
Sell 28.6 K USD
DEMANE MICHAEL F
Director
- 300
95.1733 USD
7 years ago
Apr 03, 2017
Sell 610 K USD
Galligan Andrew H
Chief Financial Officer
- 6537
93.3866 USD
7 years ago
Apr 03, 2017
Sell 865 K USD
Galligan Andrew H
Chief Financial Officer
- 9166
94.3235 USD
7 years ago
Apr 03, 2017
Sell 1.36 M USD
Galligan Andrew H
Chief Financial Officer
- 14297
95.0403 USD
7 years ago
Mar 06, 2017
Sell 72.7 K USD
Enxing Michael
VP of Sales
- 800
90.9038 USD
7 years ago
Mar 06, 2017
Sell 55.4 K USD
Enxing Michael
VP of Sales
- 600
92.3533 USD
7 years ago
Mar 06, 2017
Sell 3.37 M USD
Enxing Michael
VP of Sales
- 37000
90.989 USD
7 years ago
Mar 06, 2017
Sell 9.28 K USD
Enxing Michael
VP of Sales
- 100
92.85 USD
7 years ago
Mar 01, 2017
Sell 3.99 M USD
JAEGER WILFRED E
Director
- 42033
95.0333 USD
7. News
Nevro Stock May Gain on the CE Mark Certification for HFX iQ NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025. zacks.com - 1 day ago
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro. prnewswire.com - 1 day ago
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level. zacks.com - 4 days ago
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system. prnewswire.com - 4 days ago
Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Shagun Singh - RBC Capital Markets Robbie Marcus - JPMorgan Matt Taylor - Jefferies Brandon Vazquez - William Blair Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Richard Newitter - Truist Securities David Rescott - Baird Operator Good afternoon. My name is Krista, and I will be your conference operator today. seekingalpha.com - 5 days ago
Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago. zacks.com - 5 days ago
Nevro Reports Third-Quarter 2024 Financial Results Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. prnewswire.com - 5 days ago
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research  demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN. prnewswire.com - 2 weeks ago
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro. prnewswire.com - 1 month ago
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. prnewswire.com - 1 month ago
Here's Why you Should Retain Nevro Stock in Your Portfolio Now Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock. zacks.com - 1 month ago
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI. zacks.com - 1 month ago
8. Profile Summary

Nevro Corp. NVRO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 169 M
Dividend Yield 0.00%
Description Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Contact 1800 Bridge Parkway, Redwood City, CA, 94065 https://www.nevro.com
IPO Date Nov. 6, 2014
Employees 1215
Officers Ms. Shana D. Ross M.B.A. Senior Vice President & Chief Human Resources Officer Mr. Christofer Christoforou Senior Vice President & Chief Operating Officer Ms. Angeline C. McCabe Vice President of Investor Relations & Corporate Communications Dr. David Caraway M.D., Ph.D. Senior Vice President & Chief Medical Officer Mr. Peter A. Socarras Vice President, General Counsel & Corporate Secretary Mr. Roderick H. MacLeod Senior Vice President & Chief Financial Officer Mr. Kevin R. Thornal President, Chief Executive Officer & Director Mr. Greg Siller Senior Vice President & Chief Commercial Officer